Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Sartorius Stedim Biotech SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sartorius Stedim Biotech SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius Stedim Biotech SA
PAR:DIM
Cash from Financing Activities
€2.3B
CAGR 3-Years
447%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pcas SA
PAR:PCA
Cash from Financing Activities
-€23.8m
CAGR 3-Years
N/A
CAGR 5-Years
-130%
CAGR 10-Years
-35%
Eurofins-Cerep SA
PAR:ALECR
Cash from Financing Activities
-€5.7m
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
-17%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Market Cap
17B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Sartorius Stedim Biotech SA's Cash from Financing Activities?
Cash from Financing Activities
2.3B EUR

Based on the financial report for Jun 30, 2024, Sartorius Stedim Biotech SA's Cash from Financing Activities amounts to 2.3B EUR.

What is Sartorius Stedim Biotech SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
447%

Over the last year, the Cash from Financing Activities growth was 671%. The average annual Cash from Financing Activities growth rates for Sartorius Stedim Biotech SA have been 447% over the past three years .

Back to Top